Henry Schein(US:HSIC)2026-02-24 21:42Business Segments - The company operates through three reportable segments: Global Distribution and Value-Added Services, Global Specialty Products, and Global Technology[18]. - The Global Distribution and Value-Added Services segment includes distribution to the global dental and medical markets, offering over 300,000 products and shipping approximately 150,000 cartons daily[37]. - The Global Specialty Products segment focuses on dental implants, biomaterials, orthodontics, and endodontics, with a presence in approximately 90 countries[38]. - The Global Technology segment contributed 5.1% to total sales in 2025, up from 4.9% in 2023[40]. Financial Performance - Net sales for the year ended December 27, 2025, increased to $13,184 million, up from $12,673 million in 2024, representing a growth of 4.0%[373]. - Gross profit for 2025 was $4,105 million, compared to $4,016 million in 2024, reflecting a gross margin of approximately 31.1%[373]. - Operating income rose to $653 million in 2025, an increase from $621 million in 2024, indicating a growth of 5.1%[373]. - Net income attributable to Henry Schein, Inc. for 2025 was $398 million, up from $390 million in 2024, marking a 2.1% increase[373]. - Total assets as of December 27, 2025, were $11,215 million, compared to $10,218 million in 2024, reflecting a growth of 9.8%[370]. - Total liabilities increased to $6,421 million in 2025 from $5,381 million in 2024, representing a rise of 19.4%[370]. - Cash and cash equivalents increased to $156 million in 2025, up from $122 million in 2024, a growth of 28.0%[370]. - Earnings per share (diluted) for 2025 was $3.27, compared to $3.05 in 2024, reflecting an increase of 7.2%[373]. Market Trends - The health care distribution industry is benefiting from macro trends such as an aging population and increased health care awareness, which stimulate demand for products and services[21]. - Customer consolidation is leading to more procedures being performed in alternate care settings, favoring distributors that provide a broad array of products at competitive prices[22]. - The U.S. population aged 45 and older is expected to grow by approximately 10% between 2025 and 2035, driving demand for health care services[45]. Compliance and Regulatory Environment - Compliance with evolving governmental regulations remains a priority, as changes could impact operations and financial performance[57]. - The Drug Supply Chain Security Act (DSCSA) requires trading partners to maintain electronic documentation for prescription drugs, with a stabilization period extended to November 27, 2024[61]. - The FDA has set new deadlines for compliance with DSCSA requirements, including May 27, 2025, for manufacturers and repackagers, and August 27, 2025, for wholesale distributors[61]. - The EU Medical Device Regulation (EU MDR) imposes stricter compliance requirements for medical devices, including enhanced traceability and post-market surveillance[72]. - The transitional period for certain medical devices under the EU MDR has been extended until December 31, 2027, for higher-risk devices[75]. - The FDA's unique device identification (UDI) system mandates that medical devices include UDIs on labels and packages, with compliance timelines varying by device risk classification[64]. - Compliance with legal requirements may lead to delays in product release or distribution, potentially resulting in financial losses and reputational harm[77]. - The company is subject to heightened enforcement activity regarding the storage, sale, and distribution of controlled substances under the Controlled Substances Act[65]. - Antitrust and consumer protection laws may result in civil and criminal penalties for violations, impacting the company's operations[78]. Employee Relations and Culture - The company employs over 25,000 people, with approximately 48% based in the United States and 52% outside the United States[116]. - About 14% of the company's employees are subject to collective bargaining agreements, indicating strong labor relations[116]. - The company has implemented a continuous listening program, including The Pulse Global Culture Survey, to gather feedback from employees on their experience[118]. - The company's inclusive culture was identified as a top strength in The Pulse Global Culture Survey for the fourth consecutive time in 2025[121]. - The company aims to foster a connected and caring community for employees, enhancing their sense of inclusion, belonging, and purpose[120]. Strategic Initiatives - The company aims to increase penetration of its existing customer base, which exceeds one million customers worldwide[46]. - The company plans to pursue strategic acquisitions and joint ventures to enhance its geographic footprint and access new products and technologies[46]. - The company is focused on expanding its dental full-service model and medical offerings in new markets through direct sales and partnerships[50]. Cash Flow and Investments - Net cash provided by operating activities increased to $712 million in 2025 from $500 million in 2023, reflecting a 42% increase[1]. - Cash used in investing activities decreased to $400 million in 2025 from $1,135 million in 2023, indicating a reduction of 65%[1]. - Net cash used in financing activities was $188 million in 2025, a significant improvement compared to $701 million provided in 2023[1]. - The company maintained a strong balance sheet and diversified investments to manage credit risks effectively[345]. Foreign Currency and Interest Rate Risks - As of December 27, 2025, the fair value of forward foreign currency exchange agreements was $(20) million, with net investment designated EUR/USD forward contracts having notional values of approximately €300 million[347]. - A hypothetical increase of 25 basis points in the average outstanding balance of the revolving credit facility would increase interest expense by $0.5 million[352]. - A 5% increase in the value of the Euro to the USD would decrease the fair value of the forward contracts by $18 million[347].